MX2019005450A - Composiciones y metodos farmaceuticos. - Google Patents
Composiciones y metodos farmaceuticos.Info
- Publication number
- MX2019005450A MX2019005450A MX2019005450A MX2019005450A MX2019005450A MX 2019005450 A MX2019005450 A MX 2019005450A MX 2019005450 A MX2019005450 A MX 2019005450A MX 2019005450 A MX2019005450 A MX 2019005450A MX 2019005450 A MX2019005450 A MX 2019005450A
- Authority
- MX
- Mexico
- Prior art keywords
- promoter
- methods
- subject
- pharmaceutical compositions
- inhibitor
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 abstract 8
- 229940097396 Aminopeptidase inhibitor Drugs 0.000 abstract 3
- 102000002704 Leucyl aminopeptidase Human genes 0.000 abstract 3
- 108010004098 Leucyl aminopeptidase Proteins 0.000 abstract 3
- 229940122110 Tyrosine hydroxylase inhibitor Drugs 0.000 abstract 3
- 230000004663 cell proliferation Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
- A61K38/34—Melanocyte stimulating hormone [MSH], e.g. alpha- or beta-melanotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Emergency Medicine (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15/351,966 US10272068B2 (en) | 2012-01-17 | 2016-11-15 | Pharmaceutical compositions and methods |
| PCT/US2017/061682 WO2018093820A1 (en) | 2016-11-15 | 2017-11-15 | Pharmaceutical compositions and methods for the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019005450A true MX2019005450A (es) | 2019-07-04 |
Family
ID=60570232
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019005450A MX2019005450A (es) | 2016-11-15 | 2017-11-15 | Composiciones y metodos farmaceuticos. |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP3541411A1 (enExample) |
| JP (2) | JP2019537608A (enExample) |
| KR (2) | KR20190084291A (enExample) |
| CN (1) | CN110167580A (enExample) |
| AU (1) | AU2017361080A1 (enExample) |
| BR (1) | BR112019009799A2 (enExample) |
| CA (1) | CA3040922A1 (enExample) |
| EA (1) | EA201991192A1 (enExample) |
| IL (1) | IL266486A (enExample) |
| MX (1) | MX2019005450A (enExample) |
| PH (1) | PH12019500758A1 (enExample) |
| WO (1) | WO2018093820A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020276605A1 (en) | 2019-05-14 | 2022-01-20 | Tyme, Inc. | Compositions and methods for treating cancer |
| CA3157855A1 (en) * | 2019-10-15 | 2021-04-22 | Tyme, Inc. | Alkylesters of alpha-methyl-dl-tyrosine for use in treating cancer |
| AU2021207666A1 (en) * | 2020-01-17 | 2022-09-01 | Tyme, Inc. | Tyrosine derivatives for modulating cancer |
| CN111358777A (zh) * | 2020-02-24 | 2020-07-03 | 军事科学院军事医学研究院环境医学与作业医学研究所 | 一种提高外周血单个核细胞线粒体功能的方法和应用 |
| US10905698B1 (en) | 2020-05-14 | 2021-02-02 | Tyme, Inc. | Methods of treating SARS-COV-2 infections |
| WO2022120039A2 (en) * | 2020-12-02 | 2022-06-09 | Steven Hoffman | Compositions and methods for modulating cancer in non-human mammals |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225435A (en) | 1990-05-18 | 1993-07-06 | Yale University | Soluble melanin |
| US20060078494A1 (en) * | 2004-09-24 | 2006-04-13 | Sapphire Therapeutics, Inc. | Use of inhibitors of 24-hydroxylase in the treatment of cancer |
| WO2006032299A1 (en) * | 2004-09-24 | 2006-03-30 | Susanna Miettinen | Use of inhibitors of 24-hydroxylase in the treatment of cancer |
| US8481498B1 (en) * | 2012-01-17 | 2013-07-09 | Steven Hoffman | Pharmaceutical compositions and methods |
| US20130183263A1 (en) * | 2012-01-17 | 2013-07-18 | Steven Hoffman | Pharmaceutical compositions and methods |
| ES2706070T3 (es) * | 2012-01-17 | 2019-03-27 | Tyme Inc | Terapia de combinación para el tratamiento del cáncer |
| US9585841B2 (en) * | 2013-10-22 | 2017-03-07 | Tyme, Inc. | Tyrosine derivatives and compositions comprising them |
-
2017
- 2017-11-15 KR KR1020197016782A patent/KR20190084291A/ko not_active Ceased
- 2017-11-15 EP EP17808688.0A patent/EP3541411A1/en not_active Withdrawn
- 2017-11-15 WO PCT/US2017/061682 patent/WO2018093820A1/en not_active Ceased
- 2017-11-15 AU AU2017361080A patent/AU2017361080A1/en not_active Abandoned
- 2017-11-15 JP JP2019524973A patent/JP2019537608A/ja active Pending
- 2017-11-15 CA CA3040922A patent/CA3040922A1/en active Pending
- 2017-11-15 EA EA201991192A patent/EA201991192A1/ru unknown
- 2017-11-15 CN CN201780070447.8A patent/CN110167580A/zh active Pending
- 2017-11-15 MX MX2019005450A patent/MX2019005450A/es unknown
- 2017-11-15 BR BR112019009799A patent/BR112019009799A2/pt not_active Application Discontinuation
- 2017-11-15 KR KR1020227043322A patent/KR20230003314A/ko not_active Ceased
-
2019
- 2019-04-08 PH PH12019500758A patent/PH12019500758A1/en unknown
- 2019-05-06 IL IL266486A patent/IL266486A/en unknown
-
2022
- 2022-11-18 JP JP2022184577A patent/JP2023018029A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| CN110167580A (zh) | 2019-08-23 |
| EA201991192A1 (ru) | 2019-10-31 |
| JP2019537608A (ja) | 2019-12-26 |
| JP2023018029A (ja) | 2023-02-07 |
| IL266486A (en) | 2019-07-31 |
| CA3040922A1 (en) | 2018-05-24 |
| BR112019009799A2 (pt) | 2019-08-06 |
| WO2018093820A1 (en) | 2018-05-24 |
| KR20190084291A (ko) | 2019-07-16 |
| EP3541411A1 (en) | 2019-09-25 |
| PH12019500758A1 (en) | 2019-07-24 |
| KR20230003314A (ko) | 2023-01-05 |
| AU2017361080A1 (en) | 2019-05-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12014501639B1 (en) | Pharmaceutical compositions and methods | |
| PH12019500758A1 (en) | Pharmaceutical compositions and methods for the treatment of cancer | |
| PH12020551923A1 (en) | Methods and compositions for treating cancer | |
| PH12022551013A1 (en) | Pyridazinones as parp7 inhibitors | |
| PH12017500070A1 (en) | Methods of treating cancer using tigit inhibitors and anti-cancer agents | |
| MX2020013649A (es) | Composiciones y metodos para inhibir la actividad de la arginasa. | |
| EP4234551A3 (en) | Pyridazinones as parp7 inhibitors | |
| PH12019500521A1 (en) | Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer | |
| MX2021013830A (es) | Inhibidores de ezh2 para tratar linfomas. | |
| EA201890961A1 (ru) | Комбинированная терапия для лечения злокачественных новообразований | |
| AU2016293674B2 (en) | A novel approach for treatment of cancer using immunomodulation | |
| SG10201907164SA (en) | Rna containing composition for treatment of tumor diseases | |
| AU2018347307A1 (en) | Heterocyclic compounds and uses thereof | |
| MX2017001656A (es) | Combinaciones de inhibidor de tirosina cinasa de bruton y usos de estas. | |
| EA201890957A1 (ru) | Комбинированная терапия для лечения злокачественных опухолей | |
| MX2017010595A (es) | Métodos, composiciones, y equipos para tratamiento de cáncer. | |
| MX2018002344A (es) | Metodo para tratar el cancer. | |
| MX2018007266A (es) | Combinaciones para el tratamiento del cancer. | |
| PH12021551036A1 (en) | Anti-liv1 immune cell cancer therapy | |
| MX2019013862A (es) | Terapia de combinacion. | |
| HK1258319A1 (zh) | 癌症疗法 | |
| MX2022002699A (es) | Lurbinectedina en el tratamiento del mesotelioma maligno. | |
| MX2020001727A (es) | Terapia de combinacion. | |
| MX2021012418A (es) | Compuestos heterociclicos y sus usos. | |
| MX2020012782A (es) | Inhibidor de ccr5 para el uso en el tratamiento de cancer. |